← Back to Search

Dietary Supplement

Flax "milk" for Cardiotoxicity (CANFLAX Trial)

N/A
Waitlist Available
Led By Davinder S Jassal, MD
Research Sponsored by St. Boniface Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if a drink made from flaxseeds can prevent heart problems in women with early-stage breast cancer who are undergoing specific chemotherapy treatments. The nutrients in flaxseeds may help protect their hearts from damage. Flaxseed has been studied for its potential cardiovascular benefits, including reducing blood pressure, lowering cholesterol levels, and protecting against heart disease.

Eligible Conditions
  • Cardiotoxicity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Left ventricular ejection fraction (LVEF) change

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Oat fibre "milk"Experimental Treatment1 Intervention
A total of 30 women will receive the oat fiber "milk" on a daily basis for a total of 4 months. The oat fibre "milk" will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water.
Group II: Flax "milk"Experimental Treatment1 Intervention
A total of 30 women will receive flax (FLX) "milk" on a daily basis for a total of 4 months. The FLX "milk" will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3.

Find a Location

Who is running the clinical trial?

St. Boniface HospitalLead Sponsor
54 Previous Clinical Trials
14,974 Total Patients Enrolled
2 Trials studying Cardiotoxicity
378 Patients Enrolled for Cardiotoxicity
Davinder S Jassal, MDPrincipal InvestigatorUniversity of Manitoba
~12 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top